MedTrace Logo

Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma

NCT03730740 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2020-10-22

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of lenalidomide maintenance therapy in patients with T-cell lymphoma who have undergone more than one treatment or relapsed after treatment and who acquired a response of more than a partial response after rescue chemotherapy. This is a phase 2 clinical trial.

Conditions

  • Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma

Interventions

DRUG

Lenalidomide 25mg

Lenalidomide 25mg, day 1 - day 21 (1cycle=28days) for 2yeas

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Won-seog Kim, MD, Ph.D · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-16
Primary Completion
2021-11-30
Completion
2023-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03730740 on ClinicalTrials.gov